Antibiotics in Chronic Obstructive Pulmonary Disease (COPD)
NCT ID: NCT00952861
Last Updated: 2010-08-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
140 participants
INTERVENTIONAL
2009-10-31
2010-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Targeted AntiBiotics for Chronic Pulmonary Diseases
NCT03262142
Prophylactic Antibiotic Treatment of Patients With Chronic Obstructive Lung Disease (COLD)
NCT00132860
Use of MULTIplex PCR, Procalcitonin, and Sputum Appearance to Reduce Duration of Antibiotic Therapy During Severe COPD EXAcerbation: A Controlled, Randomized, Open-label, Parallel-Group, Multicenter Trial
NCT05280132
Procalcitonin To Reduce Antibiotics in Chronic Obstructive Lung Disease (ProToCOLD)
NCT01950936
A Trial of Procalcitonin in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease
NCT04682899
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Doxycycline
Doxycycline 200 mg QD in 5 days
Doxycycline
200 mg QD in 5 days
Placebo
Matching placebo QD i 5 days
Placebo (matching)
Placebo QD i 5 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Doxycycline
200 mg QD in 5 days
Placebo (matching)
Placebo QD i 5 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* History of smoking
* History of COPD
* Antibiotics for 24 hours
* At least 2 of the following: dyspnoea, coughing with sputum, and sputum with purulence
* Informed consent
Exclusion Criteria
* Antibiotics for more than 36 hours
* Antibiotics for other infection
* Prednisolone, more than 0.5 mg/kg body weight/24 hours for more than 3 days
* Malignancy
* Other pulmonary disease
* Immune deficiency
* Not able to tolerate doxycycline
* Severe heart, liver or kidney disease
* Epilepsia
* Not stable 24 hours after hospital admission
* Need for assisted ventilation
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kolding Sygehus
OTHER
Svendborg Hospital
OTHER
Fredericia Hospital
UNKNOWN
Naestved Hospital
OTHER
Hillerod Hospital, Denmark
OTHER
Region Syddanmark
OTHER
Danmarks Lungeforening
OTHER
Danish National Research Foundation
OTHER
Odense University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Department of Infectious Diseases, Odense University Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Court Pedersen, MD
Role: STUDY_CHAIR
Odense University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Odense University Hospital
Odense, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
OUH-INF-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.